ArticlePloS one2026
Evaluating cord blood S100B protein concentration as a potential biomarker associated with fetal hypoxia in late fetal growth restriction: A prospective cohort study protocol.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06893926 (Evaluating the Utility of S100B Protein Concentration for Diagnosing Fetal Central Nervous System Hypoxia-Ischemia in Children With Late Fetal Growth Retardation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Utility of S100B Protein Concentration for Diagnosing Fetal Central Nervous System Hypoxia-Ischemia in Children With Late Fetal Growth Retardation: A Prospective Cohort Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionS100B protein is a biomarker associated with central nervous system (CNS) injury following hypoxic-ischemic events. Measurement of S100B levels in umbilical cord blood may provide a noninvasive means of identifying newborns exposed to perinatal hypoxia related to fetal growth restriction (FGR) immediately after birth. Early detection of infants at increased risk of hypoxia-related CNS injury could facilitate closer surveillance, prompt diagnostic evaluation, and timely implementation of appropriate interventions, potentially improving long-term neurodevelopmental outcomes. METHODS AND ANALYSIS: This study investigates two groups of full-term pregnancies: a study group with prenatally diagnosed late FGR, and a control group with normal fetal growth. Following delivery, cord blood samples from both groups will be analyzed for S100B protein concentrations, pH, base excess (BE), and lactate levels. Additionally, fetal blood flow parameters in the umbilical artery (UA), uterine arteries (UtA), ductus venosus (DV), and middle cerebral artery (MCA) will be assessed via ultrasound within 48 hours before delivery. This study aims to compare S100B protein concentrations in umbilical cord blood between the two groups and evaluate its correlations with fetal Doppler parameters, pH, BE, and lactate levels in cord blood gas analysis. Additionally, it will evaluate the potential utility of S100B protein concentration as a biomarker associated with perinatal hypoxic stress in FGR-affected neonates. ETHICS AND DISSEMINATION: The study received approval from the Bioethics Committee of the Institute of Mother and Child in Warsaw (Decision No. 13/2024, dated 21 March 2024). The findings will be submitted for publication in peer-reviewed journals specializing in neonatology, pediatrics, obstetrics, and perinatology. Additionally, abstracts will be submitted to relevant national and international conferences.
trial registrationThe study is registered at ClinicalTrials.gov (Identifier: NCT06893926).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.